# US 2021/0238256 A1 · Fusion protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0238256 A1
- Document ID: US20210238256A1
- Status: Published application
- Kind: A1
- Application number: 17/211,362
- Filed: 2021-03-24
- Published: 2021-08-05
- Earliest claimed: 2016-03-16
- Assignees: Levicept LTD
- Applicants: Levicept Limited
- Inventors: Simon WESTBROOK
- Web page: https://patentgrep.com/patent/US20210238256A1

## CPC

- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G01N 2800/28: Neurological disorders
- G01N 2800/2807: Headache; Migraine
- G01N 2800/2842: Pain, e.g. neuropathic pain, psychogenic pain
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a p75NTR neurotrophin binding protein (NBP)-Fc fusion protein comprising a p75NTR(NBP) portion and an immunoglobulin portion. In certain embodiments, the p75NTR(NBP)-Fc fusion protein is for use in the treatment of pain and/or a symptom of pain.

## Claims

### Claim 1

A p75NTR neurotrophin binding protein (NBP)-Fc fusion protein, comprising:
(a) a p75NTR(NBP) portion; and
(b) an immunoglobulin Fc portion.

### Claim 2 (depends on 1)

The p75NTR(NBP)-Fc fusion protein according to claim 1, wherein the p75NTR(NBP) and Fc portions are connected via a linker.

### Claim 3 (depends on 2)

The p75NTR(NBP)-Fc fusion protein according to claim 2, wherein the linker comprises a peptide of formula Gx, where x is 1, 2, 3, 4, 5 or 6.

### Claim 4 (depends on 1, 2, 3)

The p75NTR(NBP)-Fc fusion protein according to any one of claims 1 to 3, wherein the p75NTR(NBP) is a human p75NTR(NBP).

### Claim 5 (depends on 1, 2, 3, 4)

The p75NTR(NBP)-Fc fusion protein according to any one of claims 1 to 4, wherein the Fc is a human Fc.

### Claim 6

The p75NTR(NBP)-Fc fusion protein according to any preceding claim, comprising or consisting of the amino acid sequence set forth in SEQ ID NO:3.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The p75NTR(NBP)-Fc fusion protein according to any one of claims 1 to 5, comprising or consisting of the amino acid sequence set forth in SEQ ID NO:15.

### Claim 8

The p75NTR(NBP)-Fc fusion protein according to any preceding claim wherein the p75NTR(NBP) binds to any of NGF, BDNF, NT3 or NT4/5 with a binding affinity (Kd) of between about 0.01 nM to about 50 nM as measured by surface plasmon resonance at 20° C.

### Claim 9

The p75NTR(NBP)-Fc fusion protein according to any preceding claim for use in the treatment of pain or a symptom of pain.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A nucleic acid molecule encoding the p75NTR(NBP)-Fc fusion protein according to any one of claims 1 to 8, optionally further comprising encoding a signal sequence.

### Claim 11 (depends on 10)

A replicable expression vector for transfecting a cell, optionally a mammalian cell, the vector comprising the nucleic acid molecule of claim 10.

### Claim 12 (depends on 11)

The replicable expression vector of claim 11 wherein the vector is a viral vector.

### Claim 13 (depends on 10)

A host cell harbouring the nucleic acid molecule of claim 10.

### Claim 14 (depends on 10, 11, 12)

The nucleic acid molecule according to claim 10 or the vector according to either of claim 11 or 12 for use in the treatment of pain or a symptom of pain.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The p75NTR(NBP)-Fc fusion protein according to any one of claims 1 to 8 or claim 9 or the nucleic acid or vector according to any one of claims 10 to 14, wherein the p75NTR(NBP)-Fc fusion protein or nucleic acid molecule or vector is for separate, sequential or simultaneous use in a combination combined with a second pharmacologically active compound.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14)

A pharmaceutical composition, comprising the p75NTR(NBP)-Fc fusion protein according to any one of claims 1 to 8 or claim 9 or the nucleic acid molecule or vector according to claims 11 to 14, and a pharmaceutically acceptable carrier and/or an excipient.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A kit comprising:
(a) the p75NTR(NBP)-Fc fusion protein according to any one of claims 1 to 8 or claim 9 or the nucleic acid molecule or vector according to claims 10 to 14; and
(b) instructions for the administration of an effective amount of said the p75NTR(NBP)-Fc fusion protein, nucleic acid molecule, vector or pharmaceutical composition to an individual for any one or more of the prevention or treatment of pain and/or a symptom of pain or for ameliorating, controlling, reducing incidence of, or delaying the development or progression of pain and/or a symptom of pain.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of treating and or preventing pain and or a symptom of pain in an individual comprising administering to said individual a therapeutically effective amount of the p75NTR(NBP)-Fc fusion protein according to any one of claims 1 to 8 or claim 9 or the nucleic acid molecule or vector according to claims 10 to 14, optionally further comprising a pharmaceutically acceptable carrier.
